Tecan and Enigma Diagnostics Sign Licence and Collaboration Agreement

By Enigma Diagnostics Limited, PRNE
Monday, January 10, 2011

MANNEDORF, Switzerland, January 11, 2011 - The Tecan Group (SIX Swiss Exchange: TECN), a leading global provider of
laboratory instruments and solutions, and Enigma Diagnostics Limited, the
decentralised and point-of-care molecular diagnostics company, announced
today the signing of a licence and collaboration agreement. The licence
provides Tecan with access to specific Enigma intellectual property that is
used in Enigma's fully automated, molecular diagnostic system, the Enigma(R)

The licence enables Tecan to further expand its growing OEM partnering
business and develop a next generation molecular diagnostics platform for a
potential OEM partner. The envisaged integrated solution includes enabling
consumables and is targeted at central laboratories with the goal to provide
a unique combination of features such as, random sample access, complete
automation from raw sample to result, a small footprint and a rapid time to

Thomas Bachmann, CEO of Tecan, said: "We are delighted to have signed
this licence agreement with Enigma for their innovative sample preparation
and thermocycling technology. The licence provides us with the opportunity to
approach a potential OEM partner with our concept of an integrated solution
for molecular diagnostics that includes a unique instrument as well as
enabling consumables. The licence agreement builds on our existing agreement
with Enigma that we signed in February 2010 for the manufacturing and supply
of Enigma(R)'s ML point-of-care molecular diagnostics instruments."

John McKinley, Chairman and CEO of Enigma, said: "We are very pleased to
sign this significant agreement which extends an already strong partnership
with Tecan. It demonstrates the capability of Enigma's sample preparation and
thermocycling technology to generate a pipeline of next generation molecular
diagnostic instruments covering high throughput, central laboratory to point
of care settings."

Financial terms were not disclosed.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory
instruments and solutions in biopharmaceuticals, forensics, and clinical
diagnostics. The company specializes in the development, production and
distribution of instruments and automated workflow solutions for laboratories
in the life sciences sector. Its clients include pharmaceutical and
biotechnology companies, university research departments, forensic and
diagnostic laboratories. As an original equipment manufacturer, Tecan is also
a leader in developing and manufacturing OEM instruments and components that
are then distributed by partner companies. Founded in Switzerland in 1980,
the company has manufacturing, research and development sites in both Europe
and North America and maintains a sales and service network in 52 countries.
In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR
259.6 million
). Registered shares of Tecan Group are traded on the SIX Swiss
Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

    For further information:

    Tecan Group
    Martin Braendle
    Head of Corporate Communications & Investor Relations
    Tel. +41-0-44-922-84-30
    Fax  +41-0-44-922-88-89

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation
rapid molecular diagnostic instrument platforms for decentralized and
point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and
sensitivity of real-time PCR (polymerase chain reaction) with the simplicity
needed for decentralized and point-of-care testing providing results from a
raw sample in less than 60 minutes. The Company is targeting a number of
multi-billion pound markets, core among which are the Clinical and high-value
Applied Markets. Enigma's commercialisation strategy is to maximize revenues
from a continuous flow of market leading rapid diagnostic point-of- care
instrument and assay platforms, based on unique technologies and underpinned
by its broad Intellectual Property portfolio. Enigma will partner with market
leaders where global penetration of markets is required and where
appropriate, will engage regional partners and build in-house sales and
marketing capability to direct distribution of its products.

    For further information:

    Enigma Diagnostics
    Josephine Deniau
    Communications Manager
    Tel: +971-4446-2367

Tecan Group: Martin Braendle, Head of Corporate Communications & Investor Relations, +41-0-44-922-84-30, Fax +41-0-44-922-88-89, investor at tecan.com; or Josephine Deniau, Communications Manager, Enigma Diagnostics, +971-4-446-2367, communications at enigmadiagnostics.com

Health Care / Hospitals News

Enigma Diagnostics Limited News

will not be displayed